[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352908-105":59,"doc-detail-352908-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bridging-mechanism-and-clinic-unlocking-the-full-potential-of-oncolytic-virus-based-immunotherapy","Bridging mechanism and clinic - unlock the full potential of oncolytic virus-based immunotherapy","","Oncolytic viruses (OVs) function as a distinctive class of cancer therapeutics by combining direct tumor cell lysis with broad immune activation, reshaping antitumor immunity beyond conventional approaches. Clinical translation is still limited by inefficient delivery, restricted tumor selectivity, premature immune clearance, and safety concerns, collectively reducing efficacy. Advances in genetic engineering, viral retargeting, and high-dimensional profiling clarify molecular and microenvironmental determinants of OV tropism and activity, enabling improved OV design and clinical outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bridging-mechanism-and-clinic-unlocking-the-full-potential-of-oncolytic-virus-based-immunotherapy/352908/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bridging-mechanism-and-clinic-unlocking-the-full-potential-of-oncolytic-virus-based-immunotherapy/352908.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What roles do oncolytic viruses play in cancer therapy?","Question",{"text":112,"@type":113},"Oncolytic viruses couple direct tumor cell lysis with broad immune activation, reshaping antitumor immunity beyond conventional modalities.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is clinical translation of oncolytic viruses still challenging?",{"text":117,"@type":113},"Key constraints include inefficient delivery, limited tumor selectivity, premature immune clearance, and safety concerns that reduce overall therapeutic efficacy.",{"name":119,"@type":110,"acceptedAnswer":120},"Which recent advances help improve oncolytic virus design and performance?",{"text":121,"@type":113},"Genetic engineering, viral retargeting, and high-dimensional profiling have clarified molecular and microenvironmental determinants of OV tropism and activity, supporting optimization of OV design.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352908,1790211916,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Hua et al. Molecular Cancer (2026) 25:126 Molecular Cancer  \n[https://doi.org/10.1186/s12943-026-02651-4](https://doi.org/10.1186/s12943-026-02651-4)  \nREVIEW Open Access  \nBridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy  \nXinru Hua1†, Hengyi Tang1†, Kaijie Liang1†, Jian Li1,2*, Xiaotian Zhang1,2,3*, Lin Shen1,2* and Cheng Zhang1,2*  \nAbstract  \nOncolytic viruses (OVs) have emerged as a distinctive class of cancer therapeutics capable of coupling direct tumor cell lysis with broad immune activation, thereby reshaping antitumor immunity beyond the capacities of conventional modalities. Despite substantial progress, the clinical translation of OVs remains constrained by challenges such as inefficient delivery, restricted tumor selectivity, premature immune clearance and  \nsafety concerns, all of which collectively limit therapeutic efficacy. Recent advances in genetic engineering,  \nviral retargeting and high-dimensional profiling technologies have begun to clarify the molecular and microenvironmental determinants of OV tropism and activity, providing new opportunities to optimize OV design. In this review, we synthesize current OV classifications, mechanisms of action and clinical developments, and highlight emerging innovations spanning synthetic engineering, targeted delivery platforms and combination therapy strategies—including those integrating OVs with immunotherapies, targeted agents and conventional modalities—to amplify therapeutic potency and overcome resistance. Together, these perspectives provide an integrated framework for understanding OV biology, underscore the need to address persistent barriers to safe and effective clinical deployment, and outline key priorities for advancing OVs toward their potential as a foundational component of next-generation, personalized cancer immunotherapy.  \nKeywords Oncolytic viruses, Immunotherapy, Tumor microenvironment, Targeted delivery, Clinical trials, Combination therapy  \n†Xinru Hua, Hengyi Tang and Kaijie Liang contributed equally to this work.  \n*Correspondence:  \nJian Li [oncogene@bjmu.edu.cn](oncogene@bjmu.edu.cn)[ ](oncogene@bjmu.edu.cn)Xiaotian Zhang [zhangxiaotian@bjmu.edu.cn](zhangxiaotian@bjmu.edu.cn)[ ](zhangxiaotian@bjmu.edu.cn)Lin Shen [shenlin@bjmu.edu.cn](shenlin@bjmu.edu.cn)[ ](shenlin@bjmu.edu.cn)Cheng Zhang [qenya_z@bjmu.edu.cn](qenya_z@bjmu.edu.cn)  \n1Department of Gastrointestinal Oncology, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, 100142 Beijing, China  \n2Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, 52 Fucheng Road,  \nBeijing 100142, China  \n3Department of Gastrointestinal Oncology, Peking University Cancer Hospital (Inner Mongolia Campus)/Affiliated Cancer Hospital of Inner Mongolia Medical University, Hohhot, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](h","cbCainPwH7UEm2Mo","https://ap.wps.com/l/cbCainPwH7UEm2Mo","pdf",3066470,26,"English","# Abstract\n# Introduction","[{\"question\":\"What roles do oncolytic viruses play in cancer therapy?\",\"answer\":\"Oncolytic viruses couple direct tumor cell lysis with broad immune activation, reshaping antitumor immunity beyond conventional modalities.\"},{\"question\":\"Why is clinical translation of oncolytic viruses still challenging?\",\"answer\":\"Key constraints include inefficient delivery, limited tumor selectivity, premature immune clearance, and safety concerns that reduce overall therapeutic efficacy.\"},{\"question\":\"Which recent advances help improve oncolytic virus design and performance?\",\"answer\":\"Genetic engineering, viral retargeting, and high-dimensional profiling have clarified molecular and microenvironmental determinants of OV tropism and activity, supporting optimization of OV design.\"}]","Bridging mechanism and clinic - unlock the full potential of oncolytic virus-based immunotherapy | PDF",1790101953,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f6d1c658d38eb76f19e2d48928cf4fc.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f187e4c2856caddf98644452c782b6cd.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f948431e082781a56afe08a71807426.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cee480a438b2343d4d71cfa28fe4ee54.webp",980,1306]